Search Results

BioCapital

ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management

ImmuneBridge, a developer of allogeneic, off-the-shelf cellular immunotherapies, has launched a new electronic lab notebook from Sapio Sciences, LLC.

November 20, 2023

·

3 min read

Biotech Bay

ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies

ImmuneBridge today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany.

April 11, 2023

·

4 min read

Pictured: NK cells attacking a cancer cell/ selvanegra

Drug Development

Can NK Cell Therapy Avoid CAR-T’s Shortcomings?

While NK cell therapies can potentially avoid the serious side effects sometimes seen with CAR T cell therapies, experts say durability may stall their path to the market.

May 27, 2024

·

5 min read

·

Aayushi Pratap

Policy

FDA Authorizes Invivyd’s Pemgarda to Prevent COVID-19 in Immunocompromised People

The regulator has allowed for emergency use of Invivyd’s monoclonal antibody Pemgarda as a COVID-19 pre-exposure prophylaxis for moderately or severely immunocompromised patients.

March 25, 2024

·

2 min read

·

Tristan Manalac

Drug Development

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™.

January 9, 2023

·

7 min read

Drug Development

Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its primary vaccination Phase II study in the Philippines and heterologous booster vaccination Phase II study in United Arab Emirates in respect of its recombinant COVID-19 vaccine ReCOV.

November 8, 2022

·

8 min read

Drug Development

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)Dosing to Resume Immediately

Ocugen, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™.

May 23, 2022

·

7 min read